Paul Tudor Jones’s Viridian Therapeutics VRDN Stock Holding History

Paul Tudor Jones’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Buy	+62,184	New	+$1M	﹤0.01%	2324
2026 Q1	–	Sell	-51,597	Closed	-$1.61M	–	4335
2025 Q4	$1.61M	Buy	+51,597	New	+$1.42M	﹤0.01%	1972
2025 Q1	–	Sell	-38,367	Closed	-$735K	–	3725
2024 Q4	$735K	Buy	38,367 +1,106	+3%	+$24K	﹤0.01%	1955
2024 Q3	$848K	Buy	+37,261	New	+$609K	﹤0.01%	1725
2024 Q1	–	Sell	-30,218	Closed	-$658K	–	2833
2023 Q4	$658K	Buy	+30,218	New	+$477K	0.01%	1643
2023 Q2	–	Sell	-24,110	Closed	-$613K	–	2957
2023 Q1	$613K	Buy	+24,110	New	+$773K	0.01%	1502

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Paul Tudor Jones's VRDN Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 62,184 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #2324 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in VRDN as recently as Q4 2025.

Paul Tudor Jones first reported a position in VRDN in Q1 2023 and has held it in 6 quarters since. The position peaked at $1.61M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Paul Tudor Jones held 62,184 shares of Viridian Therapeutics worth $1.14M as of Q2 2026.
Viridian Therapeutics was a new Paul Tudor Jones position in Q2 2026.
Viridian Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2324 holding.
Paul Tudor Jones first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 6 quarters since.
Paul Tudor Jones's Viridian Therapeutics position peaked at $1.61M in Q4 2025.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.